Cancer - Prostate(구연) Oral Session 1 / Cancer - Prostate (Ⅰ) (O-002) Grand Ballroom(2F) 11월28일(수) 13:00-14:00 골다공증. 그것이 정말로 ADT의 부작용입니까? 부산대학교 의과대학 비뇨기과학교실 구자윤, 김경환, 백승룡, 박지훈, 강병진, 박시균, 하홍구 Purpose To investigate the occurrence rate and risk factors of bone loss in prostate cancer patients. Materials and Methods This study was conducted on 783 subjects from 2011 to 2018. Lumbar spine and femoral neck BMD testing were performed using dual-energy x-ray absorptiometry in all patients. We first compared the occurrence rate of bone loss in the hormone-naïve prostate cancer patients (n=288), and ADT-treated patients (n=136), and control group (n=359). In sub-analysis, we analyzed the risk factors in each hormone-naïve prostate cancer patients and ADT-treated patients. Results The hormone-naïve prostate cancer patients and ADT-treated patients had significantly lower BMD values and T-scores than the control group (p < 0.001). For patients who were hormone-naïve prostate cancer, ADT-treated for more than 1 years, and control group, the osteoporosis prevalence was 8.7% (25/288), 14.7% (20/136), and 5.6% (20/359), respectively. In hormone-naïve prostate cancer patients, multiple logistic regressions showed that body mass index and neutrophil were significant risk factors (p = 0.013 and p = 0.038). In addition, in ADT-treated patients, HbA1C was only significant risk factor (p = 0.033) Conclusions Bone loss is seen in prostate cancer patients regardless of ADT treatment, and then ADT treatment accelerates bone loss. Therefore, BMD testing should be considered in lower BMI and neutrophil hormone-naïve prostate cancer patients before initiating ADT. keywords : osteoporosis, BMD, PCA